List view / Grid view
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Cachexia is a condition of involuntary weight loss, undernourishment and a number of negative side-effects that can be seen in patients with Chronic obstructive pulmonary disease (COPD), as well as in cancer and in several severe inflammatory diseases, such as AIDS, congestive heart failure, tuberculosis and rheumatoid arthritis...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
In a notice from the FDA, the Prescription Drug User Fee Act date for its Priority Review of telotristat etiprate has been extended by three months...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body's immune system is missing or functions improperly...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI)...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
APX001 is a small molecule drug candidate that targets and inhibits the conserved fungal enzyme Gwt1, compromising fungal growth of major fungal pathogens...
19 September 2016 | By ABITEC Corporation
ABITEC Corporation continues to add new innovations and dosage form applications to their already expansive product portfolio...
16 September 2016 | By PCI Pharma Services
Leading pharmaceutical provider PCI Pharma Services will bring its expertize to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) with two Speakers Corner slots at the ICSE Exhibitor Showcase...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
EB-101 is the company's lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of...
16 September 2016 | By Niamh Louise Marriott,
The European Commission has approved Ibsen’s cabometyx (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx (cabozantinib) demonstrated significant clinical benefits across all three efficacy endpoints (OS, PFS, ORR) in a phase 3…
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation to Santhera Pharmaceutical’s idebenone (raxone) for the treatment of Duchenne muscular dystrophy (DMD). The product has already received ODD from European, Swiss and US authorities...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients…
